The main factors influencing canine demodicosis treatment outcome and determination of optimal therapy

作者: Milica Arsenović , Lato Pezo , Nebojša Vasić , Rodoljub Ćirić , Milan Stefanović

DOI: 10.1007/S00436-015-4543-7

关键词: Internal medicineAdverse effectAmitrazDemodicosisSurgeryIvermectinMoxidectinMilbemycin oximeMedicineTransplantationDoramectin

摘要: The main idea of this research was to evaluate the efficacy canine demodicosis conventional treatments using mathematical analyses. All available papers published between 1980 and 2014 were used in study. One hundred six clinical trials enrolling 3414 cases generalized dogs are studied. Dogs entered analysis only ones which disease occurred naturally, excluding studies transplantation Demodex canis mites done from other animals. In acaricide treatments, sorted according active substances (moxidectin, amitraz, doramectin, ivermectin, milbemycin oxime), way application (spot-on, dips, orally, or subcutaneous), concentration, interval as input parameters modeling. Data interest treatment outcome, number that went into remission, animals not responding microscopically, average duration therapy, follow-up period, patients with recurrence, adverse effects, side effects. lost when discontinued, due various reasons connection therapy protocol, considered. Statistical analyses applied for prediction drugs’ effectiveness. Developed models showed satisfactorily r 2, higher than 0.87. Good evidence recommending use oxime PO (0.5 mg/kg, daily) moxidectin spot-on (Advocate®, Bayer) weekly is found. A bit less effective therapies based on ivermectin daily), (0.35 mg/kg, amitraz dips (0.05 % solution, weekly), respectively. It important keep mind Advocate® recommended by manufacturer milder cases.

参考文章(62)
J. R. Wellington, D. W. Scott, W. H. Miller, R. Panic, Clinical efficacy of milbemycin oxime in the treatment of generalized demodicosis in adult dogs. Javma-journal of The American Veterinary Medical Association. ,vol. 203, pp. 1426- 1429 ,(1993)
I. P. Johnstone, Doramectin as a treatment for canine and feline demodicosis Australian Veterinary Practitioner. ,vol. 32, pp. 98- 103 ,(2002)
N E White-Weithers, Z Ristic, M Paradis, L Medleau, Ivermectin for treatment of generalized demodicosis in dogs. Javma-journal of The American Veterinary Medical Association. ,vol. 207, pp. 1308- 1310 ,(1995)
Seward Rl, Todd Ks, Tranquilli Wj, Paul Aj, DiPietro Ja, Clinical observations in collies given ivermectin orally. American Journal of Veterinary Research. ,vol. 48, pp. 684- 685 ,(1987)
Tara E. Paterson, Richard E. Halliwell, Paul J. Fields, Marta Lanza Louw, Jakobus P. Louw, Geoff S. Ball, Rhonda D. Pinckney, John S. McKibben, Treatment of canine-generalized demodicosis: a blind, randomized clinical trial comparing the efficacy of Advocate® (Bayer Animal Health) with ivermectin Veterinary Dermatology. ,vol. 20, pp. 447- 455 ,(2009) , 10.1111/J.1365-3164.2009.00803.X
Ralf S. Mueller, Daniela Meyer, Emmanuel Bensignor, Carola Sauter-Louis, Treatment of canine generalized demodicosis with a 'spot-on' formulation containing 10% moxidectin and 2.5% imidacloprid (Advocate®, Bayer Healthcare). Veterinary Dermatology. ,vol. 20, pp. 441- 446 ,(2009) , 10.1111/J.1365-3164.2009.00790.X
Tatjana Živičnjak, A retrospective evaluation of efficiency in therapy for generalized canine demodicosis Veterinarski Arhiv. ,vol. 75, pp. 303- 310 ,(2005)
G. E. P. Box, D. W. Behnken, Some New Three Level Designs for the Study of Quantitative Variables Technometrics. ,vol. 2, pp. 455- 475 ,(1960) , 10.1080/00401706.1960.10489912
S.D. Folz, D.D. Kratzer, L.H. Nowakowski, R.D. Conklin, D.L. Rector, Evaluation of a topical treatment, alone and in combination with a detergent, for generalized demodicosis Veterinary Parasitology. ,vol. 17, pp. 165- 172 ,(1985) , 10.1016/0304-4017(85)90103-7